The results suggest that targeted treatments used in rare epilepsies might also work in a portion of patients with common forms of the disease.
The results begin to adress questions about whether the company's meticulous, but costly research services can actually impact patient outcomes.
By overlaying epilepsy genetic data onto co-expressed gene networks from post-mortem brain samples, researchers proposed a 320-gene expression network for epilepsy.
The company plans to release its first product in this area, a blood-based proteomic diagnostic for epilepsy, as a laboratory-developed test next year.
The test, named EvoScore START, measures a panel of blood-based protein biomarkers to distinguish between epileptic seizures and other similar events.
The Geisinger Health System team found 241 genes, including 17 new ones, which could be related to autism, schizophrenia, and other disorders.
In Genome Biology this week: height-mediated mate choice genetics, method for predicting pathogenic mutations, and more.
A team of New York University-led researchers has developed a screen for mosaic mutations.
The service will entail follow-up in vitro modeling and research for individuals with an identified, but ill-understood genetic variant related to a rare disorder.
A recent study determined a particular geneset was the best method to normalize RT-qPCR data from a specific model system, with caveats.
In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.
Technology Review points out that a new US presidential science advisor hasn't been selected.
Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.
President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.